These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 26099603

  • 1. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.
    Zhang S, Zhang Y, Liu P, Zhang W, Ma JL, Wang J.
    Clin Rheumatol; 2016 Jan; 35(1):151-8. PubMed ID: 26099603
    [Abstract] [Full Text] [Related]

  • 2. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.
    Schumacher HR, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, Tate GA, Molina J.
    BMJ; 2002 Jun 22; 324(7352):1488-92. PubMed ID: 12077033
    [Abstract] [Full Text] [Related]

  • 3. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 22; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 4. Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial.
    Li T, Chen SL, Dai Q, Han XH, Li ZG, Wu DH, Zhang X, Gu JR, Yang NP, Sun LY, Zhang MJ, Li XF, Bao CD.
    Chin Med J (Engl); 2013 Dec 22; 126(10):1867-71. PubMed ID: 23673101
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X, Tian M, Zhang W, Mei H.
    PLoS One; 2018 Dec 22; 13(1):e0190798. PubMed ID: 29320568
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis.
    Li M, Yu C, Zeng X.
    BMJ Open; 2020 Sep 10; 10(9):e036748. PubMed ID: 32912981
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
    Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, Pryhuber KG, Lund M, Chen E, Najarian DK, Petruschke RA, Ozturk ZE, Geba GP.
    Arthritis Rheum; 2004 Feb 18; 50(2):598-606. PubMed ID: 14872504
    [Abstract] [Full Text] [Related]

  • 9. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee.
    Am Heart J; 2006 Aug 18; 152(2):237-45. PubMed ID: 16875903
    [Abstract] [Full Text] [Related]

  • 10. [Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain].
    Zolotovskaya IA, Davydkin IL.
    Ter Arkh; 2015 Aug 18; 87(12):18-25. PubMed ID: 26978413
    [Abstract] [Full Text] [Related]

  • 11. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 18; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout.
    Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM.
    Curr Med Res Opin; 2007 Jul 18; 23(7):1685-91. PubMed ID: 17588299
    [Abstract] [Full Text] [Related]

  • 20. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
    van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA.
    Arthritis Res Ther; 2015 Mar 19; 17(1):66. PubMed ID: 25879879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.